



April 01, 2024

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Dear Sirs,

In terms of Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of Press Release being issued by the Company on the following subject:

**‘Jubilant Ingrevia Limited Commissions New Facility for Diketenes & Derivatives’**

Date of occurrence event- March, 31 2024

Time of occurrence- 21:10

We request you to take the same on records.

Thanking you,

Yours faithfully,  
For Jubilant Ingrevia Limited

Deepanjali Gulati  
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Ingrevia Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantingrevia.com](http://www.jubilantingrevia.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
Uttar Pradesh, India  
CIN : L24299UP2019PLC122657



**Jubilant Ingrevia Limited**

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

[www.jubilantingrevia.com](http://www.jubilantingrevia.com)

---

## **JUBILANT INGREVIA LIMITED COMMISSIONS NEW FACILITY FOR DIKETENES & DERIVATIVES**

**STRENGTHENS PROFILE IN SPECIALTY CHEMICALS SEGMENT; POSITIONS ATTRACTIVELY  
FOR ACCELERATED GROWTH FROM ADVANCED, HIGH-POTENTIAL CHEMISTRY  
PLATFORMS**

---

**Noida, UP, India, March --, 2024:** Jubilant Ingrevia Limited, today announced the commissioning of a new facility at its manufacturing site for Diketene derivatives at Gajraula, Uttar Pradesh. As a global, integrated life science products and innovative solutions provider, the Company presently has over 134 products & innovative solutions commercialised. With over four decades of experience, it has developed proficiency across ~35 key chemistry and technology platforms across its businesses: Specialty, Nutrition and Chemical Intermediates.

The newly commissioned facility adds additional capacity of ~2,000 TPA to produce high-value esters. This strengthening of the Diketene and derivatives platform marks a natural evolution of strategy in the Specialty Chemicals segment. This business is pivoting towards accelerated growth and higher margins with the introduction of several downstream derivatives.

In line with its long-term strategic objectives, Jubilant Ingrevia remains committed to commissioning of future phases of Diketene derivatives. In addition to existing clients the expanded range of diketene derivatives will be aimed at a new category of customers in key international markets, including the U.S and E.U regions.

**On this occasion, Mr. Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited, said, “I am delighted to emphasise our unwavering dedication to specialty chemicals business with the introduction of this new facility. Diketene and derivatives represent an accelerated growth platform for us. We are committed to cultivating a comprehensive range of advanced product portfolio within this segment with about half a dozen existing derivatives and several new ones in pipeline. Today’s announcement marks an inflection in growth as this advancement will bring us closer to satisfying our client’s needs for innovative products and solutions, leveraging a distinctive and specialised chemistry platform”.**

Whereas the existing range of offerings in diketene and derivatives has ramped up markedly, the next iteration of growth shall come from introduction of new products that are presently in the pipeline. The Company’s long-standing association with leading customers in pharmaceuticals, agrochemicals and other industries combined with early efforts to get customer product approvals, are expected to drive major portion of capacity utilisation in the coming months.

---

## **About Jubilant Ingrevia Limited**

*Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.*

*The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The Company has over 2,300 employees and serves more than 1,600 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.*

*Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers. For more information, please visit: [www.jubilantingrevia.com](http://www.jubilantingrevia.com).*

---

### **For more information please contact:**

---

#### *For Investors:*

*Pavleen Taneja*

*Jubilant Ingrevia Limited*

*Ph: +91-120 436 1000*

*E-mail: [pavleen.taneja@jubl.com](mailto:pavleen.taneja@jubl.com)*

*Siddharth Rangnekar / Mit Shah*

*CDR India*

*Ph: +91 97699 19966 / 99201 68314*

*E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[mit@cdr-india.com](mailto:mit@cdr-india.com)*

#### *For Media & Press:*

*Sudhakar Safaya*

*Ph: +91 120 436 1062*

*E-mail: [sudhakar.safaya@jubl.com](mailto:sudhakar.safaya@jubl.com)*

*Ryan Marshall*

*Madison Public Relations*

*Ph: +91 9810047944*

*E-mail: [ryan.marshall@madisonpr.in](mailto:ryan.marshall@madisonpr.in)*

**Disclaimer:** *Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*

---